Other antihyperglycemic drugs without a potential for hypoglycemia, such as metformin, dipeptidyl-peptidase-4 (DPP-4) inhibitors (gliptins), sodium-glucose cotransporter‐2 (SGLT-2) inhibitors (gliflozins), glitazones and glukagon-like peptide‐1 (GLP-1) receptor agonists as well as dual GLP-1/glucose-dependent insulinotropic peptide (GIP) receptor agonists are not associated with such a time limitation. This evidence concerns the gene SLC5A2 and Hypoglycemia.